Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesBernard Zinman, Silvio E. Inzucchi|New England Journal of Medicine|2015Cited by 11.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionJohn J.V. McMurray, Anna-Maria Langkilde, Pardeep S. Jhund et al.|New England Journal of Medicine|2019Cited by 6.8k
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered ApproachSilvio E. Inzucchi, David R. Matthews|Diabetes Care|2012Cited by 3.2k
American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic ControlEtie S. Moghissi, Guillermo E. Umpierrez, Mary T. Korytkowski et al.|Diabetes Care|2009Cited by 1.5k
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trialsColin Baigent, Faı̈ez Zannad, Jonathan Emberson et al.|The Lancet|2022Cited by 969